{"ok":true,"entity":{"id":"labcorp","name":"Labcorp Holdings Inc.","entityType":"company","officialName":"Labcorp Holdings Inc.","canonicalName":"Labcorp Holdings Inc.","displayName":"Labcorp Holdings Inc.","category":"臨床検査・医薬品開発支援会社（米国）","shortDescription":"臨床検査（Diagnostics Laboratories）と製薬向け受託検査（Biopharma Laboratory Services）を手がけるNYSE上場企業（LH）。2026年7月30日発表の2026年第2四半期の売上高は37.31億ドル（前年同期35.27億ドル、+5.8%）で、通期ガイダンスを引き上げた。2025年3月には欧州の診断大手SYNLABの間接的な少数株式（15%）の取得を完了している。","primaryCluster":"healthcare","parentEntity":null,"verificationStatus":"draft","website":"https://www.labcorp.com/","updatedAt":"2026-10-13T05:36:43.320Z","secondaryClusters":[],"alias":["Labcorp","ラブコープ"],"searchKeywords":["Labcorp","ラブコープ","Laboratory Corporation of America","LH","臨床検査","米国 臨床検査会社","Biopharma Laboratory Services","Diagnostics Laboratories","SYNLAB 出資"]},"referenceIndex":["P-01-001","P-02-001","P-04-001","P-05-001","P-06-001"]}